APTO - Aptose stock rises as HM43239 gets FDA fast track status to treat blood cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Aptose Biosciences' (NASDAQ:APTO) HM43239 to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. The company said the oral drug is currently being evaluated in an international phase 1/2 trial to treat patients with R/R AML. Aptose noted that HM43239 had received the FDA's orphan drug designation in 2018 to treat AML, a cancer of the blood and bone marrow. APTO +7.50% to $1.29 premarket May 4

For further details see:

Aptose stock rises as HM43239 gets FDA fast track status to treat blood cancer subtype